RE:AgainPersonally, I think the macro environment is having a HUGE impact on this stock. At the end of the day its a penny stock that trades on the venture exchange, so its going to be hit the hardest with any swings in sentiment in the healthcare sector. NHC, CXV, VRX, CRH etc are all down 40-60% from their recent (1 month or less) peaks. I'd say we'd be trading closer to $.90-$1.00 if it wasn't for the whole sector crashing.
Good thing this is only temporary. Once sentiment turns around (expect the health care sector to rebound in the next month or two, crash wasn't justified as many stocks were trading at relatively fair multiples, now they have become extremely cheap), and after some postive earnings news for Q4 ($33M+ Revenue and $8M+ Ebitda), we should be well on the way to $.70+ (I'd estimate within 1-3 months).
For 2016 I'd estimate revenue of $250M+ and $65M+ ebitda. This is assuming 15%-20% growth and another 3 LOI's closed in between now and next summer.
PHM is very undervalued compared to comparable companies in the health sector.